Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Stepwise genetic testing refines the diagnosis of suspected congenital dyserythropoietic anemias: A cohort study of 76 Indian families

Manu Jamwal, Ravina Taak, Prashant Sharma et al. Nov 03, 2025 pp. 4674-4674 10.1182/blood-2025-4674

Abstract Congenital dyserythropoietic anemias (CDAs) are a heterogeneous group of inherited red cell disorders characterized by ineffective...

A single-arm, open-label trial to evaluate the efficacy and safety of reduced-dose daratumumab in combination with bortezomib and dexamethasone (DVd-lite) in patients with newly diagnosed monoclonal gammopathy of renal significance (MGRS)

Huan Xie, Maoyuan Xiang, Dongfeng Zeng Nov 03, 2025 pp. 7504-7504 10.1182/blood-2025-7504

Abstract Background: Clone-directed therapy is essential for managing monoclonal gammopathy of renal significance (MGRS), as it reduces neph...

Humanized anti-CD25 monoclonal antibody for previously treated hemophagocytic lymphohistiocytosis in adults: A prospective, open-label clinical trial

Tingting Liu, Haiming Kou, Yu Hu et al. Nov 03, 2025 pp. 1226-1226 10.1182/blood-2025-1226

Abstract Hemophagocytic lymphohistiocytosis (HLH) is a rare syndrome characterized by immune dysregulation and hyperinflammation. It is asso...

Advancing adoption of evidence-based quadruplet treatment regimens for newly diagnosed multiple myeloma in community practice: Insights from a quality improvement initiative

Nisha Joseph, Muhamed Baljevic, Emily Zyborowicz et al. Nov 03, 2025 pp. 2625-2625 10.1182/blood-2025-2625

Abstract Background Quadruplet regimens (anti-CD38 monoclonal antibody added to the proteasome inhibitor and immunomodulatory drug backbone)...

Real-world clinical characteristics and treatment outcomes in PNH patients prescribed pegcetacoplan across europe, the United States and Canada

Jens Panse, Koo Wilson, Brianne Kerr et al. Nov 03, 2025 pp. 4970-4970 10.1182/blood-2025-4970

Abstract Background Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra-rare blood disease characterized by uncontrolled complement activa...

Efficacy and safety of zanubrutinib in patients with non-IgM lymphoplasmacytic lymphoma

Mika Geva, Michelle Okwali, Lorenzo Falchi et al. Nov 03, 2025 pp. 5374-5374 10.1182/blood-2025-5374

Abstract Introduction Zanubrutinib (ZANU), a second-generation BTK inhibitor, was approved in 2021 for the treatment of...

New evidence that complement activation and NLRP3 inflammasome signaling work together to cause cytokine release syndrome after CAR-T cell therapy

Diana Wierzbicka, Kannathasan Thetchinamoorthy, Jaromir Tomasik et al. Nov 03, 2025 pp. 2328-2328 10.1182/blood-2025-2328

Abstract Background: Cytokine release syndrome (CRS) is a common and potentially serious complication of chimeric antigen receptor T-cell (C...

Lenalidomide-related diarrhea is associated with gut microbiota dysbiosis and disruption of the bile acid pool

Kevin Miller, Teng Fei, Ruben Ramos et al. Nov 03, 2025 pp. 2233-2233 10.1182/blood-2025-2233

Abstract Background Lenalidomide is a cornerstone of multiple myeloma (MM) treatment, but frequently causes gastrointestinal (GI) toxicity,...

Prognostic impact of MRD negativity in AML patients treated with venetoclax-based therapy: A systematic review and meta-analysis

Shivam Patel, Pragya Jain, Nency Ganatra et al. Nov 03, 2025 pp. 1742-1742 10.1182/blood-2025-1742

Abstract TITLE: PROGNOSTIC IMPACT OF MRD NEGATIVITY IN AML PATIENTS TREATED WITH VENETOCLAX BASED THERAPY: A SYSTEMATIC REVIEW AND META ANAL...

Polygenic scores as a clinical diagnosis tool for abnormal hematological values

Marc Srour, Estelle Lecluze, Manon Saby et al. Nov 03, 2025 pp. 2567-2567 10.1182/blood-2025-2567

Abstract Background Abnormal hematological values are one of the most frequent reasons for hematological consultations....

Epidemiologic clues, current management and diagnostic trends in idiopathic budd-chiari syndrome: Implications of PNH and diagnostic testing

Aashray Mandala, Arda Durmaz, Mark Orland et al. Nov 03, 2025 pp. 1432-1432 10.1182/blood-2025-1432

Abstract Budd-Chiari Syndrome (BCS), characterized by thrombosis of the hepatic vein, is a classical complication of PNH. While BCS can be a...

Myc super-enhancer dynamics in T-ALL

Georgios Tousinas, Vasili Toliopoulos, Melissa Tracy et al. Nov 03, 2025 pp. 5030-5030 10.1182/blood-2025-5030

Abstract Mutations in non-coding regulatory elements are increasingly recognized as critical drivers of cancer development and progression....

Fixed-duration subcutaneous mosunetuzumab continues to demonstrate high rates of durable responses in patients with relapsed/refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal Phase II study

Sarit Assouline, Nancy Bartlett, Laurie Sehn et al. Nov 03, 2025 pp. 5353-5353 10.1182/blood-2025-5353

Abstract Background: In a pivotal Phase II study (NCT02500407), subcutaneous (SC) mosunetuzumab (Mosun), a CD20xCD3 T-cell engaging bispecif...

An interim assessment of bleeding events in a prospective natural history study of hereditary hemorrhagic telangiectasia patients using a validated bleeding scale and a novel daily reporting instrument

John Lee, Aysheh Alrfooh, Lynn Gallant et al. Nov 03, 2025 pp. 2702-2702 10.1182/blood-2025-2702

Abstract Background Hereditary hemorrhagic telangiectasia (HHT) is an inherited bleeding disorder characterized by recurrent hemorrhagic eve...

Assessing diagnostic accuracy of DermPathGPT01 for dermatologic diagnosis in post-allogeneic stem cell transplant patients

Ella Wesson, Kimberly Seymour, Emma Cordover et al. Nov 03, 2025 pp. 7875-7875 10.1182/blood-2025-7875

Abstract Introduction Cutaneous complications are common among patients undergoing allogeneic hematopoietic stem cell transplantation (allo-...

Exploratory analysis from HAVEN 1–4 to further contextualize injection-site reactions among people with hemophilia A receiving emicizumab

Maya Bloomberg, Katherine Eakle, Markus Niggli et al. Nov 03, 2025 pp. 4839-4839 10.1182/blood-2025-4839

Abstract Background: Long-term data with subcutaneous emicizumab prophylaxis in people with hemophilia A (PwHA) with or without factor (F)VI...

Multicenter prospective Phase II study of decitabine priming combined with low-dose idarubicin, cytarabine, and G-CSF in children with refractory or relapsed Acute Myeloid Leukemia

Liyan Fan, Xiaowen Zhai, Ningling Wang et al. Nov 03, 2025 pp. 5233-5233 10.1182/blood-2025-5233

Abstract Background: As of 2018, no standard salvage regimen had been established for pediatric relapsed or refractory acute myeloid leukemi...

Effect of the dominant-negative ikaros isoform 6 (Ik6) on cell function and drug sensitivity in acute lymphoblastic leukemia cell lines

Qishan Hao, Juan Feng, Meizhen Xu et al. Nov 03, 2025 pp. 6827-6827 10.1182/blood-2025-6827

Abstract Objective IKZF1 deletions occur commonly in patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) and predict a poo...

Healthcare utilization in patients with sickle cell disease on buprenorphine for chronic pain

Ronay Thomas, Andrea Bundy, Joseph Giannini et al. Nov 03, 2025 pp. 4376-4376 10.1182/blood-2025-4376

Abstract Introduction: Patients with sickle cell disease (SCD) often experience acute and chronic pain that necessitates...

Single-cell transcriptomic studies reveal altered heterogeneity in CD41 enriched megakaryocytes after targeted therapy in myeloproliferative neoplasm

Man Mohan, Amber Broadhurst, Rashid Mehmood et al. Nov 03, 2025 pp. 3764-3764 10.1182/blood-2025-3764

Abstract Recent single cell studies have shown that the megakaryocyte (MK) lineage is heterogeneous with multiple sub-populations such as im...

Neutropenia, infections, and mortality across Acute Myeloid Leukemia induction strategies: A single center retrospective study

Rohan Singh, Emily Davidson, Kai Sun et al. Nov 03, 2025 pp. 1601-1601 10.1182/blood-2025-1601

Abstract Introduction Infectious complications are a major cause of morbidity and mortality in acute myeloid leukemia (AML). While cytarabin...

Multiple time-point FDG-PET imaging for risk stratification of patients with relapsed/refractory large B-cell lymphoma undergoing CD19-directed CAR-T cell therapy

Evgenii Shumilov, David Ventura, Valeria Carobin et al. Nov 03, 2025 pp. 5491-5491 10.1182/blood-2025-5491

Abstract Introduction CD19-directed CAR-T cell therapy is a curative approach for patients (pts) with relapsed/refractory (r/r) large B-cell...

Temporal trends and disparities in non-Hodgkin lymphoma related mortality along the US-Mexico border from 1999 to 2020: CDC wonder analysis

Muhammad Shaheer Mannan, Allahdad Khan, Arfa Ahmad et al. Nov 03, 2025 pp. 8072-8072 10.1182/blood-2025-8072

Abstract Background: Non-Hodgkin Lymphoma (NHL) is a hematological cancer that affects the lymphatic system, and is characterized by the abn...

Baseline CD4 count is associated with early mortality in HIV-associated lymphoma: A retrospective cohort study

Emily Davidson, Olga Golubeva, Joseph Deng et al. Nov 03, 2025 pp. 3678-3678 10.1182/blood-2025-3678

Abstract Background: HIV-associated lymphomas remain a leading cause of cancer-related mortality among people living wit...

IFN-γ driven hepatic injury exacerbates mortality in NK/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis

Yu Yehua, Jun Shi Nov 03, 2025 pp. 7171-7171 10.1182/blood-2025-7171

Abstract Hepatic involvement is a life-threatening complication in natural killer/T-cell lymphoma with hemophagocytic lymphohistiocytosis (N...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page